Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open-label Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Clinical Efficacy of HY0001a for Injection in Patients With Advanced Malignant Solid Tumors

NCT07069062 is registered in ClinicalTrials.gov with Sichuan Huiyu Pharmaceutical Co., Ltd as lead sponsor.

NCT NCT07069062
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07069062 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open-label Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Clinical Efficacy of HY0001a for Injection in Patients With Advanced Malignant Solid Tumors
Lead sponsor
Sichuan Huiyu Pharmaceutical Co., Ltd
Phase
Phase 1/2
Overall status
Recruiting
Start date
July 21, 2025
Completion date
September 30, 2027
Enrollment
261 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor